Selecting a decision model for economic evaluation: A case study and review

Health Care Management Science

Volumn 1, Issue 2, 1998, Pages 133-140

  Karnon, Jonathan ^a   Brown, Jackie ^a  

^a BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; BIOMEDICAL TECHNOLOGY ASSESSMENT; BREAST TUMOR; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; FEMALE; HUMAN; METHODOLOGY; MIDDLE AGED; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; REVIEW; UNITED KINGDOM;

ADULT; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; GREAT BRITAIN; HUMANS; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 0032173753     PISSN: 13869620     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1019090401655     Document Type: Article

References (21)

1. M.J. Buxton, Health economics in the 1990's, in: Health Economics of Depression (1st ed.), eds. B. Jonsson and J. Rosenbaum (Wiley, 1993) pp. 1-13.
2. K. Blumenschein and M. Johannesson, Economic evaluation in healthcare, Pharmacoeconomics 10(2) (1996) 114-122.
3. M.J. Buxton et al., Modelling in economic evaluation: an unavoidable fact of life, Health Economics 6(3) (1997) 217-227.
4. B. Bloom, M. Buxton, M. Drummond, B. Luce and T. Sheldon, The pros and cons of modelling in economic evaluation, OHE Briefing 33 (1997) 1-12.
5. J. Fletcher, N.R. Hicks, J.D.S. Kay and P.A. Boyd, Using decision analysis to compare policies for antenatal screening for Down's syndrome, British Medical Journal 311 (1995) 351-357.
6. T.A. Lieu, S.E. Watson and A.E. Washington, The cost-effectiveness of prenatal carrier screening for cystic fibrosis, Obstetrics and Gynaecology 84(6) (1994) 903-912.
7. D.A. Revicki et al., Modelling the cost effectiveness of antidepressant treatment in primary care, Pharmacoeconomics 8(6) (1995) 524-540.
8. A.H. Briggs, M.J. Sculpher, R.P. Logan, J. Aldous, M.E. Ramsay and J.H. Baron, Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age, British Medical Journal 312(7042) (1996) 1321-1325.
9. A. Davies and K. Cuninghame, Breast Cancer: Screening and Treatment, House of Commons Library Research Division, Background Paper, 1992.
10. K.R. Fox, Adjuvant therapies for node-positive operable breast cancer, in: Breast Cancer Treatment - a Comprehensive Guide to Management (1st ed.), eds. B. Fowble, R.L. Goodman, J.H. Glick and E.F. Rosato (Mosby Year Book, 1991) pp. 265-289.
11. J.H. Glick, Adjuvant therapy for node-negative breast cancer, in: Breast Cancer Treatment - a Comprehensive Guide to Management (1st ed.), eds. B. Fowble, R.L. Goodman, J.H. Click and E.F. Rosato (Mosby Year Book, 1991) pp. 243-264.
12. M. Drummond, B. O'Brien, G. Stoddart and G. Torrance, Methods for the Economic Evaluation of Health Care Programmes (2nd ed.) (Oxford University Press, Oxford, 1997).
13. G.W. Torrance, Measurement of health state utilities for economic appraisal, Journal of Health Economics 5 (1986) 1-30.
14. National Cancer Institute, Questions and answers about adjuvant therapy for breast cancer, Cancer Facts, 1996. gopher://gopher.ncc. go.jp:70-0/CNET/All_files/600720.
15. R.D. Gelber, A. Goldhirsch and F. Cavalli, Quality of life adjusted evaluation of adjuvant therapies for operable breast cancer, Annals of Internal Medicine 114 (1991) 620-628.
16. J.R. Beck and S.G.Pauker, The Markov process in medical prognosis, Medical Decision Making 3 (1983) 419-458.
17. F.A. Sonnenberg and J.R. Beck, Markov models in medical decision making, Medical Decision Making 13(4) (1993) 322-338.
18. B.E. Hillner, Financial costs, benefits, and patient risk preferences in node-negative breast cancer: Insights from a decision analysis model, Recent Results in Cancer Research 127 (1993) 277-284.
19. B.E. Hillner and T.J. Smith, Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer -a decision-analysis model, New England Journal of Medicine 324(3) (1991) 160-168.
20. B.E. Hillner, T.J. Smith and C.E. Desch, Assessing the cost-effectiveness of adjuvant therapies in early breast cancer using a decision analysis model, Breast Cancer Research and Treatment 24 (1993) 97-105.
21. T.J. Smith and B.E. Hillner, The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women, J. Clin. Oncol. 11 (1993) 771-776.